Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented GM1 gangliosidosis diagnosis based on genotyping confirming the β-gal gene mutations and/or documented deficiency of β-gal enzyme by laboratory testing~* Children with early infantile GM1 gangliosidosis less than 12 months of age with ability to swallow~* Children with late infantile GM1 gangliosidosis less than 3 years of age with ability to sit~Exclusion Criteria:~* Uncontrolled seizure disorder. Patients who are stable on anti-convulsive medications may be included~* More than 40% brain atrophy as measured by MRI total brain volume at screening~* Current participation in a clinical trial of another investigational medicinal product~* Past participation in a gene therapy trial~* History of hematopoietic stem cell transplantation~* Any condition that would contraindicate treatment with immunosuppressant therapy~* Presence of concomitant medical condition or anatomical abnormality precluding lumbar puncture or intracisternal injection~* Presence of any permanent items (e.g., metal braces) precluding undergoing MRI~* History of non-GM1 gangliosidosis medical condition that would confound scientific rigor or interpretation of results~* Rare and unrelated serious comorbidities, e.g., Down syndrome, intraventricular hemorrhage in the new-born period, extreme low birth weight (\<1500 grams) or known bleeding disorders~* Any vaccination 1 month prior to the planned immunosuppressant treatment~* Serology consistent with HIV exposure or consistent with active hepatitis B or C infection~* Grade 2 or higher lab abnormalities for Liver function tests (LFT), bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT), and partial thromboplastin time (PTT), according to CTCAE v5.0

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- 8x10^12 vg/Kg LYS-GM101 (Type: EXPERIMENTAL): Subjects will receive a single infusion: 8x10\^12 vg/Kg LYS-GM101

Based on this trial design, predict the completion outcome and termination type (if applicable).